AbbVie

European Commission
#AbbVie #European Commission #Follicular lymphoma #Genmab

EC grants marketing authorisation to lymphoma therapy 

The European Commission (EC) has granted marketing authorisation for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of relapsed or refractory follicular lymphoma.  The combination regimen, developed by AbbVie and Genmab for the treatment of adult patients, is the first and only bispecific-based therapy approved in… Read More

#News #Regulatory

#AbbVie #Nxera Pharma #R&D

Nxera earns $10m under terms of AbbVie collaboration 

Nxera Pharma has received $10 million after a fourth R&D milestone was met in the company’s collaboration with AbbVie.  Nxera and AbbVie entered a multi-target collaboration in 2022 to  leverage Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease.   The fourth… Read More

#Business & Investment #News

#AbbVie #Cell and gene therapy #CRISPR Therapeutics #Eli Lilly #Hansa Biopharma #Resolution Therapeutics #Vertex

Cell and gene therapies – looking forward

Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area. … Read More

#Exclusive Content

#AbbVie #Funding #Pioneer Group

They’ve got a Golden Ticket: Alceus Bio wins 2025 initiative 

Biotechnology company Alceus Bio has been awarded Pioneer Group and AbbVie’s 2025 Golden Ticket.  The company, a developer of synthetic chimeric antigen receptor T-lymphocyte therapies for solid malignancies, was chosen as the winner after an extensive selection process.  The Golden Ticket provides a significant package of… Read More

#News

#AbbVie #Brain disease #Collaboration #Nxera Pharma

Nxera Pharma receives $10 million from collaboration with AbbVie

Nxera Pharma has received $10 million from pharmaceutical company AbbVie under the terms of the multi-target discovery collaboration on neurological diseases, Nxera has announced.  Nxera and AbbVie entered the multi-target collaboration in 2022, leveraging Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated… Read More

#Business & Investment #News

#AbbVie #Major depressive disorder #Mergers and acquisitions #Psychedelics #Psychiatry

AbbVie acquires psychedelic for major depressive disorder

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead asset, bretisilocin (GM-2505), a potential best-in-class compound for the treatment of major depressive disorder (MDD), for up to $1.2 billion.  Psychedelic compounds have gained recognition as potential treatments for mental health disorders, because of their demonstrated rapid, robust and… Read More

#Business & Investment #News

#AbbVie #Antibody drug conjugate (ADC) #MHRA #Oncology #Ovarian cancer

Elahere gets UK approval in platinum-resistant ovarian cancer

Elahere (mirvetuximab soravtansine) has become the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is approved in patients who have received one to three… Read More

#News #Regulatory

Monoclonal antibody
#AbbVie #Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Monoclonal antibodies #Oncology

AbbVie licenses trispecific antibody in billion-dollar contract

IGI Therapeutics, a wholly owned subsidiary of Ichnos Glenmark Innovation, and AbbVie have announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, for oncology and autoimmune diseases.  “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more… Read More

#Business & Investment #News

#AbbVie #Capstan Therapeutics #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

AbbVie acquires in vivo CAR-T technology with Capstan purchase

AbbVie has revealed it will acquire Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs.  The acquisition will include CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase… Read More

#Business & Investment #News

#AbbVie #Bristol Myers Squibb #Cerevel Therapeutics #FDA #Karuna Therapeutics #Neuroscience #Schizophrenia

Comment: Knock on effects of AbbVie’s failed schizophrenia trials

DDW’s Megan Thomas reflects on the impact of AbbVie’s failed schizophrenia trials. Earlier this month, AbbVie provided updates confirming that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, have failed in… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory

Monoclonal antibody
#AbbVie #European Commission #Follicular lymphoma #Genmab #Lymphoma #Oncology

Second lymphoma indication approval for Tepkinly in Europe

AbbVie and Genmab’s Tepkinly (epcoritamab) has been granted conditional marketing authorisation by the European Commission (EC) as a monotherapy for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. The approval makes Tepkinly the first subcutaneous T-cell engaging bispecific antibody… Read More

#News #Regulatory

Bispecific antibodies
#AbbVie #ASCO #Bispecific Antibodies #Follicular lymphoma #Genmab #Haematology #Oncology

95% response to bispecific antibody in follicular lymphoma

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More

#Cancer Research #News #Trending News

T cell attacking cancer cell
#AbbVie #CAR-T #Collaboration #Haematology #In vivo #Umoja Biopharma

Collaboration boosts development of novel in-situ CAR-T cell therapies

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. The first agreement provides AbbVie an exclusive option to license Umoja’s CD19 directed in-situ generated CAR-T cell therapy candidates. This includes UB-VV111,… Read More

#Business & Investment #News

Follicular lymphoma
#AbbVie #Bispecific Antibodies #Clinical trials #Follicular lymphoma #Genmab

New data for relapsed/refractory follicular lymphoma treatment 

Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20).   Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously in 128 adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma… Read More

#News

Bispecific antibodies
#AbbVie #Bispecific Antibodies #Cancer research #CHMP #EMA #Genmab #Haematology #Oncology

Bispecific antibody a “promising treatment option” for DLBCL

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines… Read More

#News #Regulatory

#AbbVie #ABPI #Clinical trials #Eli Lilly #Life sciences #Pharmaceutical industry #Pharmaceuticals #UK #UK government

Pharma firms pull out of UK drug pricing agreement

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going… Read More

#Business & Investment #News #Trending News